#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15234	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2119	714.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1460	1460	C	928	C,T	881,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27702	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3485	791.6	0	.	n	.	0	T695C	SNP	695	695	T	972	972	C	833	C,T	789,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27702	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3485	791.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1614	1614	A	930	A	874	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27702	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3485	791.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2248	2248	C	984	C,T	904,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27702	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3485	791.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2874	2874	T	876	T	825	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27702	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3485	791.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2322	2322	A	921	A	876	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2270	folP	852	852	100.0	folP.l15.c4.ctg.1	1472	152.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1022	1024	AGC	233;233;231	A;G;C	222;220;216	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6286	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3467	180.9	1	SNP	p	S91F	0	.	.	271	273	TCC	637	639	TCC	183;185;183	T;C,A;C	174;175,1;178	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6286	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3467	180.9	1	SNP	p	D95G	0	.	.	283	285	GAC	649	651	GAC	194;194;197	G;A;C	186;183;185	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6286	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3467	180.9	1	SNP	p	D95N	0	.	.	283	285	GAC	649	651	GAC	194;194;197	G;A;C	186;183;185	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1898	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1468	128.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	611	613	ACC	196;197;194	A;C;C	176;185;183	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1898	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1468	128.8	0	.	p	.	0	R44H	NONSYN	130	132	CGC	626	628	CAC	202;201;199	C;A;C	191;186;190	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1898	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1468	128.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	809	811	CAC	246;247;250	C;A;C	233;232;235	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1898	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1468	128.8	1	SNP	p	G45D	0	.	.	133	135	GGC	629	631	GGC	201;203;205	G;G;C	194;191;192	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1046	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1025	101.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5792	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2994	192.9	1	SNP	p	D86N	0	.	.	256	258	GAC	627	629	GAC	241;241;243	G;A;C,G	222;220;219,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5792	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2994	192.9	1	SNP	p	S87W	0	.	.	259	261	AGT	630	632	AGT	245;243;241	A,C;G;T	222,1;220;219	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5792	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2994	192.9	1	SNP	p	S87R	0	.	.	259	261	AGT	630	632	AGT	245;243;241	A,C;G;T	222,1;220;219	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5792	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2994	192.9	1	SNP	p	S87I	0	.	.	259	261	AGT	630	632	AGT	245;243;241	A,C;G;T	222,1;220;219	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5792	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2994	192.9	1	SNP	p	S88P	0	.	.	262	264	TCC	633	635	TCC	239;240;243	T;C;C	217;218;222	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4716	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2784	168.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1611	1613	GGC	203;205;202	G;G;C	191;191;185	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4162	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2484	166.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1302	1304	GCA	215;215;217	G;C;A	204;208;212	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4162	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2484	166.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1305	1307	ATC	217;217;218	A;T;C	210;210;213	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4162	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2484	166.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1317	1319	GTG	217;217;219	G,A;T;G	208,1;205;211	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4162	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2484	166.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1317	1319	GTG	217;217;219	G,A;T;G	208,1;205;211	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4162	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2484	166.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1821	1823	ACC	241;239;240	A;C;C	219;226;227	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4162	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2484	166.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1875	1877	GCG	199;199;196	G;C,G;G	172;152,1;161	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4162	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2484	166.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1875	1877	GCG	199;199;196	G;C,G;G	172;152,1;161	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4162	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2484	166.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1998	2000	GGC	181;178;180	G;G;C	162;161;162	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4162	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2484	166.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2007	2009	GGC	171;168;166	G;G;C	151;152;147	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4162	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2484	166.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2025	2027	CCG	149;149;150	C,G;C;G,C	120,1;117;117,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6106	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3232	188.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2636	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1704	153.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	543	543	C	199	C	181	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3160	porB1b	1035	1035	95.92	porB1b.l15.c4.ctg.1	1509	207.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	479	481	GGA	264;263;269	G;G;A	248;247;253	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3160	porB1b	1035	1035	95.92	porB1b.l15.c4.ctg.1	1509	207.2	0	.	p	.	0	F135L	NONSYN	403	405	TTT	740	742	CTT	275;280;281	C;T;T	256;259;258	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3160	porB1b	1035	1035	95.92	porB1b.l15.c4.ctg.1	1509	207.2	0	.	p	.	0	R143G	NONSYN	427	429	AGA	764	766	GGA	290;287;286	G;G;A	267;269;265	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3160	porB1b	1035	1035	95.92	porB1b.l15.c4.ctg.1	1509	207.2	0	.	p	.	0	G189S	NONSYN	565	567	GGC	902	904	AGC	253;253;251	A;G;C	235;235;232	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3160	porB1b	1035	1035	95.92	porB1b.l15.c4.ctg.1	1509	207.2	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	968	968	T	223	T	216	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3160	porB1b	1035	1035	95.92	porB1b.l15.c4.ctg.1	1509	207.2	1	SNP	p	G120K	0	.	.	358	360	GGT	695	697	GGT	252;252;256	G,A;G,A;T,G	240,1;240,1;237,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3160	porB1b	1035	1035	95.92	porB1b.l15.c4.ctg.1	1509	207.2	1	SNP	p	A121N	0	.	.	361	363	GCC	698	700	GCC	257;257;254	G,A;C,A;C	243,1;247,1;244	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3160	porB1b	1035	1035	95.92	porB1b.l15.c4.ctg.1	1509	207.2	1	SNP	p	A121D	0	.	.	361	363	GCC	698	700	GCC	257;257;254	G,A;C,A;C	243,1;247,1;244	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10880	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4818	225.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1999	2001	AAT	240;240;237	A;A;T	230;230;226	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1226	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1102	110.8	1	SNP	p	V57M	1	.	.	169	171	ATG	525	527	ATG	240;238;236	A;T;G	229;227;227	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
